Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности коррекции хронической анемии у онкологических больных
Современные возможности коррекции хронической анемии у онкологических больных
Н.В.Жуков, И.А.Курмуков. Современные возможности коррекции хронической анемии у онкологических больных. Онкология. 2006; 2: 54-57.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004 Oct; 40 (15): 2293–306.
2. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303–11.
3. Groopman JL, Itri L. Chemotherapy induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616–34.
4. Carnot P, DeFlandre C. Sur l’activite hemopoietique de erum au cours de la regeneration du sang. C R Acad Sci (Paris) 1906; 143: 384–6.
5. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558–64.
6. Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 1985; 313: 806–10.
7. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 92: 7850–84.
8. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73–8.
9. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–9.
10. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–92.
11. Koury MJ, Bondurant MC. Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin. Transfusion 1990; 30: 673–4.
12. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; xxx–xxx.
13. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083–107.
14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v.2.2005 Cancer and Treatment Related Anemia.
15. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888–95.
16. Bohlius JF, Langensiepen S, Schwarzer G et al. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood 2003; 102: 203a [abstr 709].
17. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v.2.2005 Cancer and Treatment Related Anemia.
18. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; xxx–xxx.
19. Szucs TD, Boogaerts MA, Coiffier B et al. Cost-effectiveness of epoetin b in the management of cancer-related anaemia. Proceedings of the 6th Annual Meeting of the European Haematology Association, 21–24 June 2001, Frankfurt, Germany. Hematol J 2001; 2 (Suppl. 1): 67 (Abstr 192).
2. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303–11.
3. Groopman JL, Itri L. Chemotherapy induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616–34.
4. Carnot P, DeFlandre C. Sur l’activite hemopoietique de erum au cours de la regeneration du sang. C R Acad Sci (Paris) 1906; 143: 384–6.
5. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558–64.
6. Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 1985; 313: 806–10.
7. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 92: 7850–84.
8. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73–8.
9. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–9.
10. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–92.
11. Koury MJ, Bondurant MC. Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin. Transfusion 1990; 30: 673–4.
12. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; xxx–xxx.
13. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083–107.
14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v.2.2005 Cancer and Treatment Related Anemia.
15. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888–95.
16. Bohlius JF, Langensiepen S, Schwarzer G et al. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood 2003; 102: 203a [abstr 709].
17. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v.2.2005 Cancer and Treatment Related Anemia.
18. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; xxx–xxx.
19. Szucs TD, Boogaerts MA, Coiffier B et al. Cost-effectiveness of epoetin b in the management of cancer-related anaemia. Proceedings of the 6th Annual Meeting of the European Haematology Association, 21–24 June 2001, Frankfurt, Germany. Hematol J 2001; 2 (Suppl. 1): 67 (Abstr 192).
Авторы
Н.В.Жуков, И.А.Курмуков
НИИ КО ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
НИИ КО ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.